EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes

Mariateresa Pettinato, Alessandro Dulja iD, Silvia Colucci iD, Valeria Furiosi, Franca Fette, Andrea U Steinbicker, Martina U Muckenthaler, Antonella Nai iD, Alessia Pagani, Laura Silvestri iD

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26961 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Mariateresa Pettinato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy. Hauptthemen laut MEDLINE: Hepcidins, Tacrolimus Binding Protein 1A. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fondazione Regionale per la Ricerca Biomedica, Fondazione Cariplo, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The expression of the iron regulatory hormone hepcidin in hepatocytes is regulated by the BMP‐SMAD pathway through the type I receptors ALK2 and ALK3, the type II receptors ACVR2A and BMPR2, and the ligands BMP2 and BMP6. We previously identified the immunophilin FKBP12 as a new hepcidin inhibitor that acts by blocking ALK2. Both the physiologic ALK2 ligand BMP6 and the immunosuppressive drug Tacrolimus (TAC) displace FKBP12 from ALK2 and activate the signaling. However, the molecular mechanism whereby FKBP12 regulates BMP‐SMAD pathway activity and thus hepcidin expression remains unclear. Here, we show that FKBP12 acts by modulating BMP receptor interactions and ligand responsiveness. We first demonstrate that in primary murine hepatocytes TAC regulates hepcidin expression exclusively via FKBP12. Downregulation of the BMP receptors reveals that ALK2, to a lesser extent ALK3, and ACVR2A are required for hepcidin upregulation in response to both BMP6 and TAC. Mechanistically, TAC and BMP6 increase ALK2 homo‐oligomerization and ALK2–ALK3 hetero‐oligomerization and the interaction between ALK2 and the type II receptors. By acting on the same receptors, TAC and BMP6 cooperate in BMP pathway activation and hepcidin expression both in vitro and in vivo . Interestingly, the activation state of ALK3 modulates its interaction with FKBP12, which may explain the cell‐specific activity of FKBP12. Overall, our results identify the mechanism whereby FKBP12 regulates the BMP‐SMAD pathway and hepcidin expression in hepatocytes, and suggest that FKBP12–ALK2 interaction is a potential pharmacologic target in disorders caused by defective BMP‐SMAD signaling and characterized by low hepcidin and high BMP6 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepcidinsTacrolimus Binding Protein 1AHumansMiceAnimalsLigandsBone Morphogenetic Protein ReceptorsHepatocytesBone Morphogenetic Protein 6

Substanzen

HepcidinsTacrolimus Binding Protein 1ALigandsBone Morphogenetic Protein ReceptorsBone Morphogenetic Protein 6

Autor:innen und Institutionen

  • Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Department of Pediatric Hematology, Oncology and Immunology, Center for Translational Biomedical Iron Research - University of Heidelberg & Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany.
  • Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Johann-Wolfgang-Goethe University Frankfurt, Frankfurt am Main, Germany.
  • School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.

ORCID-Profile: Alessandro Dulja, Silvia Colucci, Antonella Nai, Laura Silvestri

Förderung

  • Fondazione Regionale per la Ricerca Biomedica
  • Fondazione Cariplo
  • Ministero della Salute
  • Deutsche Forschungsgemeinschaft
  • DFG

Zitieren

APA

Pettinato, M., Dulja, A., Colucci, S., Furiosi, V., Fette, F., Steinbicker, A. U., Muckenthaler, M. U., Nai, A., Pagani, A., & Silvestri, L. (2023). FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes. American Journal of Hematology. https://doi.org/10.1002/ajh.26961

Vancouver

Pettinato M, Dulja A, Colucci S, Furiosi V, Fette F, Steinbicker AU, et al. FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes. American Journal of Hematology. 2023. doi:10.1002/ajh.26961

BibTeX
@article{Pettinato2023,
  author = {Pettinato, Mariateresa and Dulja, Alessandro and Colucci, Silvia and Furiosi, Valeria and Fette, Franca and Steinbicker, Andrea U and Muckenthaler, Martina U and Nai, Antonella and Pagani, Alessia and Silvestri, Laura},
  title = {FKBP12 inhibits hepcidin expression by modulating BMP receptors interaction and ligand responsiveness in hepatocytes},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26961}
}
Kostenlos starten →